CFM
TGTX icon

Catalyst Funds Management’s TG Therapeutics TGTX Stock Holding History

Catalyst Funds Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$382K Buy
+6,950
New +$284K 0.02% 447
2024
Q3 		– Sell
-2,200
Closed -$39.1K – 1598
2024
Q2 		$39.1K Sell
2,200
-800
-27% -$12.8K 0.01% 483
2024
Q1 		$45.6K Buy
+3,000
New +$47.8K 0.01% 583

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Catalyst Funds Management's TGTX Position: Q2 2026 in Review

Catalyst Funds Management opened a new position in TG Therapeutics (TGTX) in Q2 2026: 6,950 shares worth $382K. The stake represents 0.02% of the portfolio and ranks #447 among its holdings. This is a return to the name: Catalyst Funds Management previously reported a position in TGTX as recently as Q2 2024.

Catalyst Funds Management first reported a position in TGTX in Q1 2024 and has held it in 3 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Catalyst Funds Management held 6,950 shares of TG Therapeutics worth $382K as of Q2 2026.
  • TG Therapeutics was a new Catalyst Funds Management position in Q2 2026.
  • TG Therapeutics made up 0.02% of Catalyst Funds Management's portfolio in Q2 2026, its #447 holding.
  • Catalyst Funds Management first reported a position in TG Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.